Julie Workman of A Sweet Life writes about six diabetes trials to keep an eye on in 2019. Ms. Workman brings our attention to JDRF and Joslin Diabetes Center as examples of research organizations working tirelessly to help progress our understanding of diabetes care and ultimately a search for cures. For example, she reports that Joslin is working on research efforts to understand the impact of nature occurring betaine supplements on risk reduction for those that would fall in the prediabetes category. We include the link and associated links to more trial information. We also include a link to Ms. Workman’s site for the full read.
Diabetes Research Connection: HA Cell Research
Diabetes Research Institute: Vitamin D & Omega-3 Study
ViaCyte: Stem Cell Control Trials in Europe
TrialSite News provides a summary of these organizations.
Joslin Diabetes Center is the world’s largest diabetes research center, diabetes clinic, and provider of diabetes education. It is located in the Longwood Medical Academic Area, Boston, Massachusetts, United States. Among the Harvard Medical School Affiliated institutions, Joslin is unique in its sole focus on diabetes. Joslin has the world’s largest team of board-certified physicians treating diabetes and its complications, as well as the largest staff of Certified Diabetes Educators anywhere in the world. Since its inception, Joslin has focused on aggressive, comprehensive care of the patient. Over 23,000 active patients receive specialty care for their eyes, hearts, kidneys, pregnancies and feet.
Joslin supports the world’s largest diabetes research team with more than 40 faculty level investigators for a total of more than 300 researchers. Joslin has 46 clinical care affiliates in the US and two in other countries.
The JDRF T1D Fund is a venture philanthropy fund accelerating life-changing solutions to treat, prevent and cure type 1 diabetes (T1D) through catalytic commercial investments. Through its investments in partnership with private capital, including venture capital, corporations and foundations, the T1D Fund seeks to attract the private investment necessary to advance drugs, devices, diagnostics, and vaccines into the hands of those living with T1D. The T1D Fund invests in areas strategically aligned with JDRF, the leading global organization funding T1D research, with an exclusive focus on supporting the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.
Diabetes Research Connection is a 501(c)(3) non profit organization headquartered in San Diego, California. Established in 2012 by five tireless proponents of diabetes research, their mission is to connect donors with early-career scientists enabling them to perform peer-reviewed, novel research designed to prevent and cure type 1 diabetes, minimize its complications and improve the quality of life for those living with the disease.
One out of every hundred Americans has type 1 diabetes. Millions of children and adults struggle with this autoimmune disease. Despite these numbers, funding for diabetes research has declined. Of the funding available, 97% goes to established scientists.
Scientific breakthroughs often emerge due to the inventiveness of early-career scientists. Albert Einstein revealed his theory of general relativity at 26. Banting & Best discovered insulin before they turned 33. Imagine our world today if these scientists had not received funding for their research? These young scientists have exciting new ideas however, mainstream funding rarely supports them, so their ideas simply can’t off the ground until the formation of this committed new nonprofit.
Diabetes Research Institute is a 501(c)(3) nonprofit organization with a mission to provide the Diabetes Research Institute with the funding necessary to cure diabetes now. The Diabetes Research Institute at the University of Miami Miller School of Medicine leads the world in cure-focused research. As the largest and most comprehensive research center dedicated to curing diabetes, the DRI is aggressively working to develop a biological cure by restoring natural insulin production and normalizing blood sugar levels without imposing other risks. Researchers have already shown that transplanted islet cells allow patients to live without the need for insulin therapy. Some study participants have maintained insulin independence for more than 10 years. The DRI is now building upon these promising outcomes by developing a DRI BioHub, a bioengineered “mini organ” that mimics the native pancreas. While various BioHub platforms are being tested in preclinical and clinical studies, the DRI is also developing strategies to eliminate the need for anti-rejection drugs and reset the immune system to block autoimmunity.